John E. Imhoff - 17 Jul 2023 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Role
Director, 10%+ Owner
Signature
/s/ John E. Imhoff
Issuer symbol
GTHP
Transactions as of
17 Jul 2023
Net transactions value
$0
Form type
4
Filing time
07 Sep 2023, 15:53:16 UTC
Previous filing
26 Jun 2023
Next filing
22 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHP Common Stock Other +26,301 +0.6% 4,436,637 17 Jul 2023 Direct F1
transaction GTHP Common Stock Purchase +500,899 +11% 4,937,536 11 Aug 2023 Direct F2
transaction GTHP Common Stock Other +112,568 +2.3% 5,050,104 21 Aug 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHP Series E Preferred Stock Purchase +250 250 11 Aug 2023 Common Stock 1,000,000 $0.2500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139.
F2 These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3)).
F3 These securities consist of Series E Convertible Preferred Stock ("Series E Preferred") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time until 8/21/2025. The Series E Preferred has no expiration date.
F4 These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777.